Patents Examined by Jake M. Vu
  • Patent number: 11903986
    Abstract: In preferred the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: February 20, 2024
    Assignee: Akrivista LLC
    Inventors: Scott Whitcup, Orest Olejnik, Michael Garst
  • Patent number: 11896721
    Abstract: An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: February 13, 2024
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Noreen Hassan
  • Patent number: 11890355
    Abstract: An ultrasound gel is provided for use with internal ultrasound imaging and/or therapy. The gel can have acoustic properties that can closely match a soft tissue to be imaged/treated and can be of a high viscosity that is maintained at body temperature. In some embodiments, the gel can act as a lubricant and, although water based, can be hydrophobic and not dissolve in bodily fluids. In some embodiments, the gel can be sterile, safe for ingestion, safe for application over mucous membranes, and include a preservative. In order to achieve sterility while maintaining a desired viscosity range, the gel can include a viscosity stabilising agent such as a viscosity protection agent for protection from radiation induced breakdown. In some embodiments, methods of altering or maintaining the viscosity of a gel is provided.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: February 6, 2024
    Assignee: Smilesonica Inc.
    Inventors: Cristian Scurtescu, Gleam Gill
  • Patent number: 11883555
    Abstract: Disclosed are: a composition for hard tissue repair with excellent penetrability to an adherend such as a cancellous bone and excellent adhesion to an adherend, which comprises a monomer (A), a polymer (B), a polymerization initiator (C) and a contrast medium (X) having a volume mean particle diameter of 3 ?m or more; and a kit for hard tissue repair having members in which the components of the monomer (A), the polymer (B), the polymerization initiator (C) and the contrast medium (X) contained in this composition for hard tissue repair are encased in three or more divided groups in an optional combination.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: January 30, 2024
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Shinya Aoki, Kengo Goto, Takashi Miura, Tetsuya Hamada, Ayako Bando
  • Patent number: 11872306
    Abstract: The present invention relates to granules of active ingredient with double taste masking, wherein the double taste masking is achieved by a hot-melt compound selected from waxes, hydrogenated vegetable oils, fatty acids, mono-, di- and triesters of fatty acids and of glycerol, triglycerides, glycerides, polyoxylglycerides, fatty alcohols, and mixtures thereof, and a thermoplastic polymer that is soluble at a pH less than or equal to 5. The invention also relates to the method for producing these granules and to orodispersible tablets containing these coated granules.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: January 16, 2024
    Assignee: Ethypharm
    Inventors: Catherine Herry, Caroline Ailhas
  • Patent number: 11872229
    Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: January 16, 2024
    Assignee: Principia Biopharma Inc.
    Inventors: Abu J. Ferdous, Mohammad R. Masjedizadeh, Wu Lin
  • Patent number: 11857683
    Abstract: The present invention relates to a lyophilized pharmaceutical composition of hydrolytically unstable pharmaceutical compounds, such as phenobarbital or salts thereof. The present invention also relates to an aqueous solution for injection of phenobarbital or salts thereof that is reconstituted from the lyophilized pharmaceutical composition. The pharmaceutical compositions of the present disclosure have an ethanol content in the range from about 5000 ppm to about 70000 ppm. The composition of the present disclosure, in certain embodiments, is stable following two years of storage, wherein the total impurities do not exceed 0.5%. The pharmaceutical compositions of the present disclosure may be used for the treatment of neonatal seizures.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: January 2, 2024
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Malay Shah, Bhushan Borole, Ravi Patel, Ajay Jaysingh Khopade
  • Patent number: 11819536
    Abstract: A composition for treating TMJ degeneration comprising a hydrogel of sclerostin and high molecular weight hyaluronic acid, or PLGA-encapsulated sclerostin, or sclerostin covalently linked to hyaluronic acid.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: November 21, 2023
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Mildred Embree, Mo Chen
  • Patent number: 11806401
    Abstract: The present invention includes a method of treating a drug-induced atrioventricular (AV) block comprising: providing a subject in need of therapy a drug that is contraindicated to treat a disease or condition in the subject, wherein the drug causes an AV block, with an amount of a lipid sufficient to reduce or eliminate the AV block caused by the drug.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: November 7, 2023
    Assignee: Signpath Pharma, Inc.
    Inventors: Lawrence Helson, Annie Bouchard
  • Patent number: 11786526
    Abstract: The invention relates to a pharmaceutical composition comprising the active ingredients rosuvastatin of formula I, with the systematic name (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid or its pharmaceutically acceptable salts, esters, hydrates or solvates, and ezetimibe of formula II, with the systematic name (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one or its pharmaceutically acceptable salts, esters, hydrates or solvates, as well as a preparation method of this pharmaceutical composition. The weight ratio of the layers is 1:2 to 2:1.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: October 17, 2023
    Assignee: SANOFI
    Inventors: Alena Prokopova, Jaroslava Svobodova, Ondrej Dammer, Petr Mikes
  • Patent number: 11679080
    Abstract: The present invention relates to a starch-free soft chew formulation for oral delivery of at least one active ingredient to an animal, and a starch-free soft chew containing the formulation and at least one active ingredient. The starch-free soft chew includes one or more active ingredients and excipients, such as a bulking agent, a flavoring agent, a humectant, a preservative, an antioxidant, and a lubricant, but no added water. In addition, the invention relates to a composition of starch-free, non-water excipients for use in the final dosage form of a soft chew for oral administration of at least one active ingredient to an animal. Also provided are processes for making the starch-free soft chew formulation and the starch-free soft chew.
    Type: Grant
    Filed: August 23, 2022
    Date of Patent: June 20, 2023
    Assignee: TGX SOFT CHEW, LLC
    Inventors: Kevin McDonnell, Joanna Rossi, Scott Eccles, Gueorgui Puchkarov
  • Patent number: 11617804
    Abstract: The present invention relates to intraoperative fluorescent imaging (IFI) used both pre-clinically using in-vivo models, as well as clinically to map sentinel lymph nodes in breast cancer, skin cancer, GI cancer, lung cancer, prostate cancer and several other cancers. IFI can be used to image solid tumors both non-specifically in hepatobiliary and breast cancers as well as in prostate and ovarian cancer. In one embodiment, two-dimensional resolution to 10 ?m2 is possible with optical imaging, significantly higher than other imaging modalities. In one embodiment, the present invention relates to a series of self-assembled nanoparticles using HLA (hyaluronic acid) as both a polymeric backbone as well as targeting ligand. In some embodiments, the present invention relates to the synthesis of HLA conjugates, and the effect of variation of the hydrophobic ligand structure and conjugation level on nanoparticle self-assembly, size, ICG loading efficiency, and ICG fluorescence quenching and reactivation.
    Type: Grant
    Filed: July 18, 2015
    Date of Patent: April 4, 2023
    Assignee: WAKE FOREST UNIVERSITY
    Inventors: Aaron Michael Mohs, Tanner Kinkade Hill, Sneha Sanjay Kelkar, Steve Kridel
  • Patent number: 11607467
    Abstract: A method of forming metal nanoparticles includes applying a substance to an area of interest, applying cold plasma to the area of interest, and synthesizing nanoparticles from the substance using the cold plasma in the area of interest, wherein the substance is a solution that contains metal ions, and the nanoparticles synthesized are metallic in nature.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: March 21, 2023
    Assignee: PLASMOLOGY4, INC.
    Inventor: Emilia M. Kulaga
  • Patent number: 11564891
    Abstract: A product for preventing and treating external genitalia infection and/or flat warts is provided, wherein the product comprises a chloroquine nanosphere. The chloroquine nanosphere comprises a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative. A mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier during preparation ranges from 1:3 to 1:5. A loading rate of the chloroquine or the chloroquine derivative in the prepared chloroquine nanosphere ranges from 3.0% to 21.6%. The water-soluble nanosphere carrier is water-soluble chitosan; a deacetylation degree of the water-soluble chitosan ranges from 80% to 95%, and a viscosity-average molecular weight thereof ranges from 3000 to 5000 g/mol. The chloroquine derivative is selected from one or more of hydroxychloroquine, chloroquine phosphate or chloroquine sulfate.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: January 31, 2023
    Assignees: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., GUANGZHOU HYBRIBIO BIOTECH LTD.
    Inventors: Longxu Xie, Xiangling Li, Manli Yuan, Ting Wang, Jianyu Wang
  • Patent number: 11484608
    Abstract: The present provides a Positional Isotopomer NMR Tracer Analysis (PINTA) method that can be used to noninvasively assess rates of hepatic mitochondrial oxidation (VCS) and/or pyruvate carboxylase (VPC) flux in a subject. In certain embodiments, the methods utilize a combined NMR/gas chromatography-mass spectrometry analysis of plasma following infusion of [3-13C]lactate and glucose tracer. The method of the invention provides investigators with a tool to non-invasively examine the role of altered hepatic mitochondrial metabolism and study the effects of therapeutic interventions for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and type 2 diabetes (T2D).
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 1, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Gerald I. Shulman, Rachel Jamison Perry, Gary Cline, Douglas Rothman, Kitt Petersen
  • Patent number: 11478421
    Abstract: The present invention relates to a starch-free soft chew formulation for oral delivery of at least one active ingredient to an animal, and a starch-free soft chew containing the formulation and at least one active ingredient. The starch-free soft chew includes one or more active ingredients and excipients, such as a bulking agent, a flavoring agent, a humectant, a preservative, an antioxidant, and a lubricant, but no added water. In addition, the invention relates to a composition of starch-free, non-water excipients for use in the final dosage form of a soft chew for oral administration of at least one active ingredient to an animal. Also provided are processes for making the starch-free soft chew formulation and the starch-free soft chew.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: October 25, 2022
    Assignee: TGX SOFT CHEW, LLC
    Inventors: Kevin McDonnell, Joanna Rossi, Scott Eccles, Gueorgui Puchkarov
  • Patent number: 11471563
    Abstract: The present disclosure relates to a method for preparing a nerve conduit, more particularly to a method for preparing a porous nerve conduit having micropores formed in microchannels and the nerve conduit prepared according to the present disclosure can be usefully used in in-vitro and in-vivo researches on nerves.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: October 18, 2022
    Assignee: Wiregene Co., Ltd.
    Inventors: Jung Keun Hyun, Kwang-Ho Lee, Jin Ho Lee, Jun-Hyeog Jang, Jonathan Campbell Knowles, Dong-Wook Han
  • Patent number: 11464858
    Abstract: Embodiments disclosed herein relate to magnetic nanoparticles having a non-narcotic analgesic, as well as methods of preparation and use thereof. A magnetically response pharmaceutical can include a core region having magnetic nanoparticles (MNPs) and a protein-based analgesic. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: October 11, 2022
    Assignee: UNIVERSITY OF WYOMING
    Inventors: Baskaran Thyagarajan, Padmamalini Baskaran
  • Patent number: 11446408
    Abstract: A biocompatible controlled release form of complexed iodine is achieved by a complexation of polyvinyl alcohol based foam and characterized by a residual starch component to optimize iodine release profiles. The resulting iodine complexed polyvinyl alcohol foam may be utilized locally as an antimicrobial agent that releases controlled amounts of iodine sufficient to kill microbes for extended durations without excessive bulk and rigidity.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: September 20, 2022
    Inventors: Solomon Rosenblatt, John P. Kennedy, Curtis E. Jones
  • Patent number: 11439589
    Abstract: Provided are: emulsion eyedrops which have no concern with possible corneal injury induced by a nonionic surfactant, have excellent thermal stability and physical stability and can contain a sparingly water-soluble drug in an increased amount; and an emulsion eyedrops stabilization method. The emulsion eyedrops contain castor oil and poly(vinyl alcohol), wherein the concentration of castor oil is 5 to 20 w/v %, the concentration of poly(vinyl alcohol) is 2 to 7 w/v %, and the ratio of the weight of castor oil to the weight of poly(vinyl alcohol) is 1.2 to 5. The emulsion eyedrops stabilization method is characterized by preparing emulsion eyedrops containing castor oil and poly(vinyl alcohol), wherein the concentration of castor oil is 5 to 20 w/v %, the concentration of poly(vinyl alcohol) is 2 to 7 w/v %, and the ratio of the weight of castor oil to the weight of poly(vinyl alcohol) is 1.2 to 5.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: September 13, 2022
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventor: Yasuhiro Mori